A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID ...
CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced ...
A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life. This makes individuals more susceptible to viral diseases like COVID ...
Auto-antibodies erroneously target their own proteins and enzymes. When these auto-antibodies target type 1 interferons, they can neutralize their function as signal proteins for the immune system.
Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results